drugset / Trial / NCT05556265

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

NCT05556265

Phase 2 Terminated 94 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.

Timeline

Start
2022-11-08
Primary completion
2024-01-06
Completion
2024-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule

Indications